Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP - Trial NCT06398873
Access comprehensive clinical trial information for NCT06398873 through Pure Global AI's free database. This phase not specified trial is sponsored by Medical University of Vienna and is currently Not yet recruiting. The study focuses on Chronic Rhinosinusitis With Nasal Polyps,Chronic Rhinosinusitis Without Nasal Polyps. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Observational
drug
Sponsor & Location
Medical University of Vienna
Timeline & Enrollment
N/A
May 15, 2024
Sep 01, 2027
Primary Outcome
Barrier function in CRSsNP and CRSwNP,Barrier function in CRSwNP with Dupilumab
Summary
The investigators aim to investigate two major so far unresolved topics in CRSwNP research:
 (1) Thorough functional and molecular characterisation of barrier function in patients
 suffering from CRSsNP and CRSwNP and (2) effect of dupilumab treatment on barrier function in
 polyp patients. This will be achieved in patient-derived samples by employing measurement of
 barrier function in primary cell cultures in combination with a mass cytometry based imaging
 approach, transcriptomic analysis as well as cytokine and microbiome data of individual
 patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06398873
Non-Device Trial